Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction.
Ragnhild HelsethOla KlevelandThor UelandRune WisethJan Kristian DamasKaspar BrochAnnika MichelsenBjørn BendzLars GullestadPål AukrustIngebjørg SeljeflotPublished in: Open heart (2021)
In patients with NSTEMI, treatment with tocilizumab is associated with increased circulating H3Cit levels, suggesting that tocilizumab enhances NETosis. Further studies should clarify whether NETosis is a relevant side effect of tocilizumab. Regardless of tocilizumab, dsDNA associated with TnT release, indicating a link between extracellular nuclear material and myocardial injury.
Keyphrases
- rheumatoid arthritis
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- st segment elevation myocardial infarction
- percutaneous coronary intervention
- disease activity
- dna methylation
- gene expression
- acute coronary syndrome
- systemic lupus erythematosus
- coronary artery disease
- atrial fibrillation
- combination therapy